

Deepak Mittal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11816572/publications.pdf>

Version: 2024-02-01

26
papers

3,194
citations

361045

20
h-index

552369

26
g-index

26
all docs

26
docs citations

26
times ranked

6654
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 123-136.	2.3	63
2	Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy. <i>Oncolmmunology</i> , 2019, 8, e1648171.	2.1	31
3	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019, 7, 559-571.	1.6	79
4	Blockade of PDGFR ² circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 85.	3.5	13
5	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. <i>Immunology and Cell Biology</i> , 2019, 97, 152-164.	1.0	29
6	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. <i>Oncolmmunology</i> , 2018, 7, e1424677.	2.1	44
7	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. <i>Oncolmmunology</i> , 2018, 7, e1445949.	2.1	46
8	Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade. <i>Cancer Discovery</i> , 2018, 8, 1066-1068.	7.7	28
9	<scp>CEP</scp> 55 is a determinant of cell fate during perturbed mitosis in breast cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	59
10	Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis. <i>Cancer Immunology Research</i> , 2017, 5, 1098-1108.	1.6	98
11	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. <i>Cancer Research</i> , 2017, 77, 5652-5663.	0.4	90
12	Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice. <i>ELife</i> , 2017, 6, .	2.8	50
13	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. <i>Cancer Research</i> , 2016, 76, 4372-4382.	0.4	130
14	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 446-459.	7.7	198
15	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. <i>Cancer Research</i> , 2016, 76, 264-274.	0.4	21
16	Interleukin-17A Promotes Arginase-1 Production and 2,4-Dinitrochlorobenzene-Induced Acute Hyperinflammation in Human Papillomavirus E7 Oncoprotein-Expressing Skin. <i>Journal of Innate Immunity</i> , 2015, 7, 392-404.	1.8	14
17	HPV16 E7 expression in skin induces TSLP secretion, type 2 ILC infiltration and atopic dermatitis-like lesions. <i>Immunology and Cell Biology</i> , 2015, 93, 540-547.	1.0	10
18	NK cells require IL-28R for optimal in vivo activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2376-84.	3.3	82

#	ARTICLE	IF	CITATIONS
19	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 2015, 36, 822-846.	4.0	242
20	Co-blockade of immune checkpoints and adenosine A _{2A} receptor suppresses metastasis. Oncolmunology, 2014, 3, e958952.	2.1	22
21	Human Papillomavirus E7 Oncoprotein Transgenic Skin Develops an Enhanced Inflammatory Response to 2,4-Dinitrochlorobenzene by an Arginase-1-Dependent Mechanism. Journal of Investigative Dermatology, 2014, 134, 2438-2446.	0.3	11
22	New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Current Opinion in Immunology, 2014, 27, 16-25.	2.4	1,163
23	Targeting Cancer-Derived Adenosine:New Therapeutic Approaches. Cancer Discovery, 2014, 4, 879-888.	7.7	256
24	Antimetastatic Effects of Blocking PD-1 and the Adenosine A _{2A} Receptor. Cancer Research, 2014, 74, 3652-3658.	0.4	217
25	Indoleamine 2,3-Dioxygenase Activity Contributes to Local Immune Suppression in the Skin Expressing Human Papillomavirus Oncoprotein E7. Journal of Investigative Dermatology, 2013, 133, 2686-2694.	0.3	50
26	TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO Journal, 2010, 29, 2242-2252.	3.5	148